Sökning: WFRF:(Gebhardt S) > Methotrexate, Doxor...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05703naa a2200889 4500 | |
001 | oai:lup.lub.lu.se:d28df80f-9433-4f99-98e7-bd5b425390d9 | |
003 | SwePub | |
008 | 160401s2015 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/75085152 URI |
024 | 7 | a https://doi.org/10.1200/JCO.2014.60.07342 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Bielack, Stefan S4 aut |
245 | 1 0 | a Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial |
264 | 1 | c 2015 |
338 | a electronic2 rdacarrier | |
520 | a Purpose EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. Patients and Methods At diagnosis, patients age ≤ 40 years with resectable high-grade osteosarcoma were registered. Eligibility after surgery for good response random assignment included ≥ two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor, < 10% viable tumor, and no disease progression. These patients were randomly assigned to four additional cycles MAP with or without IFN-α-2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS; primary) and overall survival and toxicity (secondary). Results Good response was reported in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus IFN-α-2b, n = 357), with baseline characteristics balanced by arm. A total of 271 of 357 started IFN-α-2b; 105 stopped early, and 38 continued to receive treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN-α-2b and for stopping prematurely, respectively. Median IFN-α-2b duration, if started, was 67 weeks. A total of 133 of 268 patients who started IFN-α-2b and provided toxicity information reported grade ≥ 3 toxicity during IFN-α-2b treatment. With median follow-up of 44 months, 3-year EFS for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported (MAP, n = 93; MAP plus IFN-α-2b, n = 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; P = .214) from an adjusted Cox model. Conclusion At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term follow-up for events and survival continues. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Smeland, Sigbjørn4 aut |
700 | 1 | a Whelan, Jeremy S4 aut |
700 | 1 | a Marina, Neyssa4 aut |
700 | 1 | a Jovic, Gordana4 aut |
700 | 1 | a Hook, Jane M4 aut |
700 | 1 | a Krailo, Mark D4 aut |
700 | 1 | a Gebhardt, Mark4 aut |
700 | 1 | a Pápai, Zsuzsanna4 aut |
700 | 1 | a Meyer, James4 aut |
700 | 1 | a Nadel, Helen4 aut |
700 | 1 | a Randall, R Lor4 aut |
700 | 1 | a Deffenbaugh, Claudia4 aut |
700 | 1 | a Nagarajan, Rajaram4 aut |
700 | 1 | a Brennan, Bernadette4 aut |
700 | 1 | a Letson, G Douglas4 aut |
700 | 1 | a Teot, Lisa A4 aut |
700 | 1 | a Goorin, Allen4 aut |
700 | 1 | a Baumhoer, Daniel4 aut |
700 | 1 | a Kager, Leo4 aut |
700 | 1 | a Werner, Mathias4 aut |
700 | 1 | a Lau, Ching C4 aut |
700 | 1 | a Sundby Hall, Kirsten4 aut |
700 | 1 | a Gelderblom, Hans4 aut |
700 | 1 | a Meyers, Paul4 aut |
700 | 1 | a Gorlick, Richard4 aut |
700 | 1 | a Windhager, Reinhard4 aut |
700 | 1 | a Helmke, Knut4 aut |
700 | 1 | a Eriksson, Mikaelu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-mer |
700 | 1 | a Hoogerbrugge, Peter M4 aut |
700 | 1 | a Schomberg, Paula4 aut |
700 | 1 | a Tunn, Per-Ulf4 aut |
700 | 1 | a Kühne, Thomas4 aut |
700 | 1 | a Jürgens, Heribert4 aut |
700 | 1 | a van den Berg, Henk4 aut |
700 | 1 | a Böhling, Tom4 aut |
700 | 1 | a Picton, Susan4 aut |
700 | 1 | a Renard, Marleen4 aut |
700 | 1 | a Reichardt, Peter4 aut |
700 | 1 | a Gerss, Joachim4 aut |
700 | 1 | a Butterfass-Bahloul, Trude4 aut |
700 | 1 | a Morris, Carol4 aut |
700 | 1 | a Hogendoorn, Pancras C W4 aut |
700 | 1 | a Seddon, Beatrice4 aut |
700 | 1 | a Calaminus, Gabriele4 aut |
700 | 1 | a Michelagnoli, Maria4 aut |
700 | 1 | a Dhooge, Catharina4 aut |
700 | 1 | a Sydes, Matthew R4 aut |
700 | 1 | a Bernstein, Mark4 aut |
710 | 2 | a Tumörmikromiljöb Sektion I4 org |
773 | 0 | t Journal of Clinical Oncologyg 33:20, s. 2279-2287q 33:20<2279-2287x 1527-7755 |
856 | 4 | u https://portal.research.lu.se/files/1692560/8560306x primaryx freey FULLTEXT |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/26033801?dopt=Abstractx freey FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1200/JCO.2014.60.0734x freey FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/7508515 |
856 | 4 8 | u https://doi.org/10.1200/JCO.2014.60.0734 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy